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Fludarabine (F-ara-A) is a purine analog commonly used in the treatment of indolent B
cell malignancies that interferes with different aspects of DNA and RNA synthesis. KV1.3
K+ channels are membrane proteins involved in the maintenance of K+ homeostasis
and the resting potential of the cell, thus controlling signaling events, proliferation and
apoptosis in lymphocytes. Here we show that F-ara-A inhibits KV currents in human B
lymphocytes. Our data indicate that KV1.3 is expressed in both BL2 and Dana B cell
lines, although total KV1.3 levels were higher in BL2 than in Dana cells. However, KV
currents in the plasma membrane were similar in both cell lines and were abrogated
by the specific KV1.3 channel inhibitor PAP-1, indicating that KV1.3 accounts for most
of the KV currents in these cell lines. F-ara-A, at a concentration (3.5 µM) similar to
that achieved in the plasma of fludarabine phosphate-treated patients (3 µM), inhibited
KV1.3 currents by 61 ± 6.3% and 52.3 ± 6.3% in BL2 and Dana B cells, respectively.
The inhibitory effect of F-ara-A was concentration-dependent and showed an IC50 value
of 0.36 ± 0.04 µM and a nH value of 1.07 ± 0.15 in BL2 cells and 0.34 ± 0.13 µM
(IC50) and 0.77 ± 0.11 (nH) in Dana cells. F-ara-A inhibition of plasma membrane KV1.3
was observed irrespective of its cytotoxic effect on the cells, BL2 cells being sensitive
and Dana cells resistant to F-ara-A cytotoxicity. Interestingly, PAP-1, at concentrations
as high as 10 µM, did not affect the viability of BL2 and Dana cells, indicating that
blockage of KV1.3 in these cells is not toxic. Finally, F-ara-A had no effect on ectopically
expressed KV1.3 channels, suggesting an indirect mechanism of current inhibition. In
summary, our results describe the inhibitory effect of F-ara-A on the activity of KV1.3
channel. Although KV1.3 inhibition is not sufficient to induce cell death, further research
is needed to determine whether it might still contribute to F-ara-A cytotoxicity in sensitive
cells or be accountable for some of the clinical side effects of the drug.
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INTRODUCTION
F-ara-A (Fludarabine, 9-β-D-arabinofuranosyl-2-fluoroadenine) is the most extensively used
purine analog in the treatment of indolent B cell malignancies. It is broadly used in the treatment
of chronic lymphocytic leukemia (CLL) either alone or in combination therapy, although its
use has been extended to other B lymphoproliferative disorders, including follicular lymphoma
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and mantle cell lymphoma (Lenz et al., 2004; Ungerechts
et al., 2007). F-ara-A is also used in conditioning regimens
before stem-cell transplantation therapies (Anderlini et al., 2016;
Laport et al., 2016). F-ara-A is administered to patients as
its monophosphorylated form (fludarabine phosphate), which
is a non-membrane permeable prodrug that requires to be
dephosphorylated to enter the cells, where it is phosphorylated
to the active triphosphate form, 9-β-D-arabinofuranosyl-2-
fluoroadenine-5′-triphosphate (F-ara-ATP) (Kano et al., 2000;
Gandhi and Plunkett, 2002). It has been demonstrated that
the cellular influx of the drug occurs preferentially in active
leukemia cells, although it also enters into normal cells (Barrueco
et al., 1987). F-ara-A seems to interfere with DNA synthesis, by
inhibiting DNA polymerases, primases and the ribonucleotide
reductase. However, in quiescent cells, such as CLL cells, its
cytotoxic function has been associated to the inhibition of DNA
transcription and RNA translation (Huang et al., 2000).
Recently, it has become evident the importance of ion
channels in lymphocyte function and they are considered suitable
therapeutic targets for treating leukemia and lymphoma. Ion
channels play a pivotal role setting the resting membrane
potential and, therefore, controlling Ca2+, Mg2+, and Zn2+
cell concentrations, thus regulating a plethora of cell functions
(Feske et al., 2012). The voltage-dependent potassium channel
KV1.3 is a membrane spanning protein complex with a
hydrophilic pore that opens under depolarization of the cell
generating a K+ eﬄux. KV1.3 has relevant functions in
the control of cell proliferation, apoptosis, and cell volume
regulation (Feske et al., 2012). In addition, there is evidence
indicating that KV1.3 channels are more expressed in different
types of leukemias and lymphomas, compared to that of
normal B lymphocytes, with the levels of KV1.3 expression
correlating with increased proliferation rates and overall
aggressiveness of these tumors (Comes et al., 2013; Leanza et al.,
2013).
In this report, we show that F-ara-A, one of the
chemotherapeutic drugs most extensively used in the treatment
of indolent B cell malignancies, significantly inhibits KV1.3
currents in human B lymphocytes.
MATERIALS AND METHODS
Drugs
F-ara-A (Sigma–Aldrich) was dissolved in DMSO to yield
stock solution of 35 mM from which further dilutions in the
patch-clamp external solution were made. The KV1.3 selective
inhibitor 5-(4-phenoxybutoxy)psoralen (PAP-1; Sigma–Aldrich)
was dissolved in DMSO to yield stock solution of 1 mM from
which further dilutions in the patch-clamp external solution were
made.
Cell Culture and Transient Transfection
The Burkitt’s lymphoma BL2 and the Epstein-Barr virus (EBV)-
transformed lymphoblastoid Dana cell lines were cultured in
RPMI medium supplemented with 10% FBS (Gibco), 2 mM
L-glutamine, 100 U/ml of penicillin and 100 µg/ml streptomycin
(Sigma–Aldrich). HEK-293 and COS-7 cells were cultured in
DMEM medium supplemented with 10% FBS, 100 U/ml of
penicillin and 100 µg/ml streptomycin. Ltk− cells were cultured
in DMEM supplemented with 10% FBS, 0.25 mg/ml G418
(Gibco) and 0.05 mg/ml gentamicin. Cells were maintained at
37◦C under a 5% CO2 atmosphere. HEK-293 and COS-7 cells
were co-transfected with KV1.3-pEYFP and a reporter plasmid
expressing CD8 using Fugene 6 (Promega Biotech Iberica)
following the manufacturer’s directions. Stably transfected Ltk−
cells with the gene encoding the expression of KV1.5 channel
were a gift of Dr. M. M. Tamkum (Colorado State University,
USA). Prior to electrophysiological experiments, transfected
HEK-293 cells were incubated with polystyrene microbeads
coated with an anti-CD8 antibody (Dynabeads CD8, Invitrogen),
as previously described (Gonzalez et al., 2002; Macias et al.,
2010).
Quantitative PCR (Q-PCR)
Total RNA was extracted with TRI reagent solution and
the PureLinkTM RNA mini kit and 1 µg of RNA was
reverse transcribed using 2 U Superscript II reverse
transcriptase (all from Thermo Fisher Scientific), following
the manufacturer’s directions. Q-PCR was carried out by
the Service of Genomics from our institute by means of
the Applied Biosystems 7900 HT Fast Real-Time PCR
System using a SYBR Green probe. Primers used for KV1.3
were: 5′ctggttctccttcgaactgc3′ and 3′gagaaggtggctttgctagg5′.
The relative RNA expression was calculated in relation
to 18S by the application of the Pfaﬄ analysis method
(Pfaﬄ, 2001).
Immunoblot Analysis
Murine and human cell line cells were lysed in modified
Laemmli buffer (125 mM Tris pH 6.8, 4% SDS, and 20%
glycerol) supplemented with a mixture of protease and
phosphatase inhibitors. Lysates were sonicated and protein
concentration was determined by the bicinchoninic acid
method (Pierce). Protein samples (50 µg per condition)
were supplemented with 2.5% 2-mercaptoethanol and
0.004% bromophenol blue, and subjected to SDS-PAGE
analysis and immunoblotting. The antibodies used were:
anti-KV1.3 APC-002 (1:200), anti-KV1.5 APC-004 (1:500)
(Alomone), anti-ERK2 (Santa Cruz Biotech), and horseradish
peroxidase-conjugated anti-rabbit (BioRad Laboratories).
Proteins were detected by chemiluminescence and exposure
on film. ERK2 expression was used as an internal loading
control.
Analysis of Cell Viability
Cells (106 cells ml−1; 100 µl per well) were incubated in
96-well microtiter plates and cultured in the presence of the
indicated concentrations of F-ara-A. After 48 h of culture,
cell viability was assessed by using the kit CellTiter 96©
AQUEOUS Assay, following the manufacturer’s instructions. The
spectrophotometric absorbance of each sample was measured at
490 nm using the BioTek Synergy Mx microplate reader (BioTek
Instruments).
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Electrophysiological Recordings and
Data Acquisition
The extracellular solution contained the following (in mM): NaCl
145, KCl 4, CaCl2 1.8, MgCl2 1, HEPES-Na 10, and glucose
10 (adjusted to pH 7.40 with NaOH). For recording on B
lymphocytes, the intracellular pipette filling solution contained
the following (in mM): KF 140, MgCl2 2, CaCl2 1, HEPES-
K 10 and EGTA-K 11 (pH 7.2 with KOH). For HEK-293
cells, the intracellular solution contained (in mM): aspartate-
K 80, KCl 42, phosphocreatine 3, KH2PO4 10, ATP-Mg 3,
HEPES-K 5 and EGTA-K 5 (pH 7.25 with KOH). Currents
were recorded using the whole-cell configuration of the patch-
clamp technique with a patch-clamp amplifier (Axopatch-200B,
Molecular Devices) and were stored on a personal computer
with a Digidata 1440A analog-to-digital converter (Molecular
Devices). PClamp 10 software (Molecular Devices) was used for
both data acquisition and analyses. Currents were recorded at
room temperature (21–23◦C) at a stimulation frequency of 0.1 Hz
and were sampled at 4 kHz after anti-alias filtering at 2 kHz.
The average pipette resistance ranged from 3 to 4 M. Gigaohm
seal formation was achieved by suction (2–5 G). After seal
formation, cells were lifted from the bottom of the bath, and the
membrane patch was ruptured with a brief additional suction.
Origin 8.5 (OriginLab Co) and the Clampfit utility of pClamp10
were used to perform least squares fitting and data presentation.
Degree of inhibition obtained for each drug concentration [D]
was used to calculate the IC50 and nH by fitting to a Hill
equation:
y = 1
1+ IC50[D]nH
The current-voltage relationships were obtained by the
application of 250-ms pulses from −80 to +40 mV, in 10 mV
increments, from a holding potential of −80 mV followed by
pulses to −40 mV to record deactivating tail currents, every
45 s to allow total recovery from inactivation of the channels.
Inactivation was fitted to a monoexponential process:
y = Ae(−tτ )+C
Where τ is the system time constant, A is the amplitude and C
is the baseline value. Frequency-dependent decay of the current
was analyzed applying a train of 10 pulses from −80 to +40 mV
of 250 ms in duration at a frequency of 1 Hz. The peak current of
each pulse was normalized to the peak current of the first pulse
and plotted versus the pulse number.
Statistical Analysis
GraphPad Prism v.6 was used for statistical analysis. The data
are presented as mean ± SEM. Comparisons were performed
by a Student t-test and statistical significance was set at
P < 0.05. The data and statistical analysis comply with
the recommendations on experimental design and analysis in
pharmacology (Curtis et al., 2015).
RESULTS
Expression of KV1.3 Ion Channel in BL2
and Dana Cells
Firstly, we analyzed the expression levels of KV1.3 mRNA in the
Burkitt’s lymphoma BL2 cell line and in the Dana lymphoblastoid
cell line by Q-PCR (Figure 1A). Both cell lines expressed
KV1.3 mRNA, but BL2 exhibited 2-fold more mRNA than
Dana cells. This expression pattern was also evident at protein
level, KV1.3 being more prominently expressed in BL2 cells
(Figure 1B). Recently, it has been also described the expression
and functional relevance of another potassium channel, KV1.5, in
B lymphocytes (Vallejo-Gracia et al., 2013). However, we did not
observed KV1.5 protein expression in either BL2 or Dana cells
(Figure 1C).
Electrophysiological Characterization of
KV Currents Recorded on BL2 and Dana
Cells
We analyzed the membrane passive properties of these cell lines.
The resting membrane potential values were −10.2 ± 1.8 mV,
n = 23, and −9.1 ± 1.7 mV, n = 35, P > 0.05, for BL2 and Dana
cells, respectively. Cell capacitance values, which are proportional
to the cell surface area, were also similar in both cells lines
(6.9 ± 0.8 pF, n = 26 for BL2 cells, and 5.7 ± 0.4 pF, n = 31
for Dana cells, P > 0.05). We recorded and characterized the
KV currents elicited by the channels present in BL2 and Dana
B cells. Figure 2A shows representative current traces recorded
in each cell line after applying the voltage protocol shown on
the top of the panel (see Materials and Methods). As expected
for a KV1.3-driven current, the recorded currents exhibited a
fast activation and a slow and incomplete inactivation. Moreover,
these currents were abolished by the selective KV1.3 inhibitor
PAP-1 (0.2 µM) (93.3 ± 1.2%, n = 6, for BL2 cells; 86.2 ± 1.4%,
n = 5, for Dana cells), indicating that plasma membrane KV1.3
channels are responsible for most of the KV current in these
cell lines. KV current was apparent at potentials positive to
−40 mV (Figure 2B), reaching a similar peak current amplitude
in both cell lines (317.7 ± 37.9 pA, n = 28, and 302.3 ± 29.2
pA, n = 31, P > 0.05, for BL2 and Dana cells, respectively).
The inactivation degree was also similar (59.7 ± 2.8%, n = 28,
and 59.8 ± 2.1%, n = 31, P > 0.05, for BL2 and Dana cells,
respectively). However, the inactivation kinetics was slightly
faster in BL2 cells (133.9± 7.0 ms, n= 27, versus 163.2± 8.8 ms,
n = 30, P < 0.05, for BL2 and Dana cells, respectively). One of
the main characteristics of KV1.3 channels is its slow recovery
from inactivation that induces a use-dependent decay of the
current when cells are stimulated at frequencies faster than
0.2 Hz. Figure 2C shows representative traces of current recorded
on each cell line after applying a train of pulses at +40 mV
at 1 Hz. In both cell lines, the peak current decreased in a
monoexponential manner to a similar extent (80.9 ± 1.6%,
n= 23, and 83.4± 1.2%, n= 20, P> 0.05, for BL2 and Dana cells,
respectively) (Figure 2D). In summary, both cell lines exhibited
similar currents with characteristic KV1.3 features.
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FIGURE 1 | KV1.3 and KV1.5 expression in BL2 and Dana cells. RNA and protein were extracted from the different cell lines as described in Section “Materials
and Methods.” (A) Basal KV1.3 gene expression was determined by Q-PCR using specific primers and the relative expression was calculated as the ratio of the
target mRNA to 18S mRNA by the application of the Pfaffl analysis method. For protein analysis, a total of 50 µg of protein for each sample were subjected to 8%
SDS-PAGE and immunoblotting with specific antibodies against KV1.3 (B) and KV1.5 (C). ERK2 was used as a loading control. Ltk- cells with or without the plasmid
expressing KV1.5 channels were used as a positive or negative control of KV1.5 expression, respectively.
FIGURE 2 | Electrophysiological characteristics of the KV current recorded on BL2 and Dana B lymphocytes. (A) Original current traces obtained on BL2
and Dana cells after 250 ms depolarisations from –80 mV to +40 mV, in 10 mV steps, every 45 s. (B) Current–voltage relationships obtained after plotting the
maximum amplitude of the current versus the membrane potential, for BL2 and Dana cells. (C) Use-dependent decay of the current. BL2 or Dana cells were
depolarized from –80 to +40 mV during 250 ms at a frequency of 1 Hz. (D) Plot of the maximum peak current recorded with the protocol shown in (B) versus the
number of pulse. Each point represents the mean of 5–17 experiments.
F-ara-A Inhibits the KV1.3 Current
Recorded on BL2 and Dana Cells
Cell perfusion with F-ara-A (3.5 µM) induced a decrease of the
peak KV1.3 current by 61.0 ± 6.3% (n = 10) and 52.3 ± 6.3%
(n= 6, P> 0.05) for BL2 and Dana cells, respectively (Figure 3A).
Steady-state inhibition was achieved after 6.9 ± 2.0 min (BL2
cells) and 13.9 ± 2.0 min (Dana cells).This inhibitory effect
was concentration-dependent, with similar IC50 and nH values
(Figure 3B). For BL2 cells, F-ara-A presented an IC50 value of
0.36 ± 0.04 µM and an nH value of 1.07 ± 0.15, while in Dana
cells, these values were 0.34 ± 0.13 µM and 0.77 ± 0.11. F-ara-A
(3.5 µM) did not modify any other characteristic of the current
such as the use-dependent decay at 1 Hz, the inactivation degree
or the inactivation kinetics (Table 1). Remarkably, the inhibition
of the KV1.3 currents by F-ara-A was similar in cells highly
sensitive to F-ara-A (BL2) and in cells refractory to this drug
(Dana) (Figure 3C), suggesting that KV1.3 current inhibition by
F-ara-A is not sufficient to induce cell death. To further assess
the effect of KV1.3 inhibition on cell viability, we analyzed the
effect of the KV1.3 selective inhibitor PAP-1 (IC50 for KV1.3
inhibition ∼2 nM) on BL2 cell viability (Figure 4), comparing it
with that of F-ara-A. Our data show that 0.2 µM PAP-1 abrogated
KV1.3 activity while 3.5 µM F-ara-A inhibited about 75% of
KV1.3 activity (Figure 4A). However, PAP-1 concentrations up
to 10 µM had no effect on cell viability (Figure 4B), while
F-ara-A killed 80% of the cells (Figure 4C), thus suggesting
that, at least in BL2 and Dana cells, KV1.3 inhibition is
not cytotoxic.
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FIGURE 3 | Effects of F-ara-A on BL2 and Dana KV1.3 currents and cell viability. (A) Superimposed current records obtained after depolarization of the cells
to +40 mV from –80 mV during 250 ms, in the absence or in the presence of F-ara-A (3.5 µM) on BL2 or Dana cells. (B) Concentration-effect curves obtained after
plotting the inhibition of the maximum current induced by F-ara-A versus the concentration of the drug and fitting these values to a Hill equation. The IC50 and nH
values are noted in the figure. Each point represents the mean of 5–10 experiments. (C) BL2 and Dana cells were cultured in triplicates in medium containing vehicle
control (0.02% DMSO) or with the indicated F-ara-A concentrations (0.35–14 µM). After culturing for 48 h the percentage of viable cells was determined by a
colorimetric assay considering the control condition as 100% viability.
TABLE 1 | KV1.3 current characteristics on BL2 and Dana cells in control conditions and with F-ara-A (3.5 µM).
BL2 Dana
Control F-ara-A Control F-ara-A
Inactivation time constant (ms) 127.4 ± 9.4 107.0 ± 9.7 (7) 184.8 ± 26.6 130.5 ± 15.8 (6)
Degree of inactivation (%) 51.8 ± 3.7 62.6 ± 7.2 (11) 52.7 ± 6.2 67.5 ± 3.1 (6)
Use-dependent inactivation (%) 82.3 ± 3.0 72.8 ± 6.8 (8) 84.9 ± 2.7 87.9 ± 2.9 (6)
Data is shown as mean ± SEM. Number in parentheses is the number of experiments. In all the cases, the comparison between control conditions and in the presence
of the drug was not significant (P > 0.05).
FIGURE 4 | Effects of PAP-1 and F-ara-A on BL2 current amplitude and cell viability. (A) KV1.3 current amplitude in BL2 cells in control conditions and after
perfusion with PAP-1 (0.2 µM) or F-ara-A (3.5 µM). Concentration-dependent effect of PAP-1 (B) or F-ara-A (C) on BL2 cell viability. After 24 and 48 h, the
percentage of viable cells was assessed. Vehicle-treated cells provided the value for 100% viability. The arrows indicate the concentration of the drug tested in the
electrophysiological experiments showed in (A).
Effects of F-ara-A on KV1.3 Channels
Expressed in HEK-293 Cells
To check if the inhibition of the KV1.3 function induced by
F-ara-A observed in B cells is due to a direct effect of the drug
on the channel, we transiently transfected HEK-293 cells with a
plasmid encoding the human KV1.3 channel. We had chosen the
HEK-293 cell line because it is a well-established model to study
ion channel function; they exhibit an endogenous KV current of
very small amplitude (in the pA range versus the nA range of
the transfected ones, Figure 5); and they do not express KVβ
subunits (Uebele et al., 1996). A representative family of traces
recorded on an HEK-293 cell transfected with the KV1.3 cDNA is
shown in Figure 5A. In these transfected cells, F-ara-A exhibited
very low potency to inhibit this current, causing a 3.2 ± 1.9%
reduction of KV1.3 current at 20 µM (n = 7) (Figures 5B,C)
after 27.6 ± 3.5 min of perfusion with the drug. However, this
current was abolished by the selective inhibitor PAP-1 at 0.2 µM
(89.5 ± 2.8% inhibition, n = 5). This result indicates that F-ara-
A had little effect on KV1.3 activity in HEK-293 cells ectopically
expressing this channel compared to the inhibition achieved in
endogenous KV1.3 channels in B lymphocytes. To assess whether
this lower potency effect of F-ara-A was specific of the HEK-
293 cells, we also tested F-ara-A on COS-7 cells transfected with
KV1.3, obtaining similar results (Figures 5D,E). At 20 µM, F-ara-
A had almost no inhibitory effect on the current (3.6 ± 2.3%,
n = 5). The fact that PAP-1 but not F-ara-A inhibits KV1.3
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FIGURE 5 | Effects of F-ara-A on KV1.3 channels expressed on heterologous systems. (A) Original current records of HEK-293 cells transfected with KV1.3
channels. Current was elicited after depolarizing the cell from –80 mV to +40 mV, in 10 mV steps, during 250 ms, every 45 s. Following each depolarization, cell was
repolarised to –40 mV to record tail currents. (B) Currents recorded at +40 mV, from −80 mV, before and after perfusion with F-ara-A (20 µM). (C) Concentration
dependence of KV1.3 current inhibition on HEK-293 cells induced by different concentrations of F-ara-A and by PAP-1 (0.2 µM). (D) Currents recorded at +40 mV,
from –80 mV, from a COS-7 cell transfected with KV1.3 before and after perfusion with F-ara-A (20 µM). (E) Degree of inhibition on transfected COS-7 cells. n = 5–8.
activity in KV1.3 transfected cells suggests that the effect of F-ara-
A on the channel is not due to a direct block of the channel
protein.
DISCUSSION
In this report, we show that KV1.3 is the most prominent
member of the voltage-gated K channels expressed in Burkitt’s
lymphoma BL2 cells and on EBV-transformed lymphoblastoid
Dana B cells. We have also characterized the KV currents from
BL2 and Dana cells. The KV current recorded in these cell
lines was abolished by the KV1.3 selective inhibitor PAP-1,
confirming that it is carried by KV1.3 channels. Furthermore,
the main features of the recorded current were the expected
for a KV1.3-driven current and were similar in both cell lines:
fast activation, slow inactivation and use-dependent inactivation.
Our data indicate that BL2 cells express more KV1.3 mRNA
and protein than Dana cells. However, the larger total KV1.3
protein expression on BL2 cells does not correlate with higher
KV1.3 current amplitude compared to Dana cells, since the
mean peak current amplitude was similar in both B cell
lines despite the differences in protein expression. This result
might indicate that the amount of functional KV1.3 channels
in the plasma membrane of BL2 and Dana cells are similar,
and that KV1.3 surplus in BL2 may be located at cytosolic
reservoirs (i.e., mitochondria). However, there are other non-
excluding possibilities, such as a different composition of the
modulatory machinery in each cell line. In this regard, it is
known that KV1.3 channels are modulated by different kinases
(PKA, PKC and tyrosine kinases), which decrease their current
amplitude without modifying other current characteristics (Payet
and Dupuis, 1992), as well as by other proteins, such as the
KVβ subunits (McCormack et al., 1999). Therefore, BL2 and
Dana cells may have different repertoire or different levels of
expression of these modulatory proteins that may change current
amplitude.
It is noteworthy that other Burkitt’s lymphoma cell lines, such
as Raji and Ramos, also express KV1.5 channels (Vallejo-Gracia
et al., 2013) and that KV1.3 and KV1.5 can form heterotetramers
with particular current characteristics, as it have been described
in macrophages (Vicente et al., 2003; Vicente et al., 2006;
Villalonga et al., 2010; Moreno et al., 2013). However, our
analyses assessing the presence of KV1.5 family member in BL2
and Dana cells failed to detect KV1.5 in any of them, thus ruling
out that heterotetramers could explain the differences in the
current between these two cell lines.
We also describe for the first time that F-ara-A is an inhibitor
of KV1.3 channel activity. F-ara-A is the purine analog most
extensively used in indolent B cell malignancies, such as CLL,
follicular lymphoma and mantle cell lymphoma (Gandhi and
Plunkett, 2002). F-ara-A inhibited the KV1.3 current in BL2 and
Dana B cell lines with an IC50 ∼0.3 µM. This concentration
is 10 times lower than the concentration of F-ara-A (3 µM)
achieved in patients plasma after being administered the standard
therapeutic dose of fludarabine-phosphate (25–30 mg/m2/day)
(Gandhi and Plunkett, 2002), thus indicating that inhibition
of the KV1.3 current by F-ara-A is achievable at clinical
dosages.
To determine if the observed inhibition was due to a direct
effect of F-ara-A on the KV1.3 channel protein, we expressed
KV1.3 channels on HEK-293 and COS-7 cells. The inhibitory
effect of F-ara-A on ectopically expressed KV1.3 cells was very
low, although PAP-1 could efficiently inhibit the current of
ectopic KV1.3 channels, thus indicating that the mechanism of
action of PAP-1 and F-ara-A on the KV1.3 channel is different.
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This result points to an indirect action of F-ara-A on the
channel activity rather than to a direct block of the channel
pore. A similar mechanism has been described for 15-epi-lipoxin-
A4, which efficiently decreases the KV current magnitude in
macrophages but has no effect on KV1.3, KV1.5 and Kir2.1
when ectopically expressed in HEK-293 cells (Moreno et al.,
2013). There are different possible explanations to the different
sensitivity of KV1.3 channels to F-ara-A in B cells compared to
that of ectopic systems. One could be that the channels expressed
in heterologous systems adopt a conformation that hinders the
binding of the drug. In addition, it would be possible that the
rate of conversion of the prodrug to the drug catalyzed by
the deoxycytidine kinase (Gandhi and Plunkett, 2002) is slower
in HEK-293 and COS-7 cells than in B lymphocytes. Another
possibility would be that the drug is acting on a protein or
signaling pathway that is relevant for KV1.3 activity that is
present in lymphocytes but not in HEK-293 or COS-7 cells. In
this regard, KV channels assemble with other membrane and
cytosolic proteins in the plasma membrane forming regulatory
and signaling complexes or channelosomes (David et al., 2012;
Velez et al., 2016), and their localization in specific membrane
microdomains (lipid rafts) is crucial for their function (Martens
et al., 2004; Moreno et al., 2015). Indeed, it is known that KV1.3
channels target caveolar structures in the cell membrane that
regulate their activity (Vicente et al., 2008; Perez-Verdaguer et al.,
2016a). Thus, the KV1.3 channelosome in HEK-293 and COS-7
cells may lack a component that is present in B lymphocytes
and that is required for the inhibition of the current induced by
F-ara-A. Similar arguments have been proposed for the reduced
sensitivity of KV1.3 channels to modulation by PKA and PKC in
HEK-293 cells compared to T lymphocytes (Martel et al., 1998).
KV1.3 channels are currently considered as new targets for
the treatment of cancer. KV1.3 expression is increased in some
human malignancies, such as breast and colon cancer (Perez-
Verdaguer et al., 2016b) and CLL (Leanza et al., 2013), and KV1.3
inhibition has been shown to induce cell apoptosis (Chandy
et al., 2004; Wulff et al., 2009; Teisseyre et al., 2015) and cell
proliferation blockage (Cahalan and Chandy, 2009). However,
our results showing that F-ara-A is similarly effective inhibiting
the KV1.3 currents generated by channels located in the plasma
membrane of B cells that are either sensitive (BL2) or resistant
(Dana) to F-ara-A, suggest that this activity is not sufficient to
explain the cytotoxic activity of F-ara-A. Furthermore, we show
that the inhibition of KV1.3 channels in BL2 cells with a selective
KV1.3 inhibitor (PAP-1) at concentrations ranging from 10 nM
to 10 µM does not induce cell death (IC50 for KV1.3 inhibition
∼2 nM). This result indicates that KV1.3 channel inhibition
is not cytotoxic in these cells. This result is in contrast with
a previous study in which PAP-1 induced death in CLL cells
(Leanza et al., 2013). However, the concentration of PAP-1 used
in this study was higher (20 µM) and it was used in combination
with inhibitors of the multidrug resistance pumps.
Nevertheless, we cannot rule out that KV1.3 inhibition by
F-ara-A might contribute to the ability of the drug to promote
cell death in F-ara-A-sensitive cells, such as BL2, or whether
this inhibitory activity might be responsible for some of the
clinical side effects of the drug. It is noteworthy that, despite the
broad clinical usage of F-ara-A, its mechanism of action is not
fully understood, although the interference with DNA and RNA
synthesis would likely underlie its cytotoxic activity.
In summary, the results described herein unveil the effect of
F-ara-A on KV1.3 channel activity in human B cell lymphoma
and lymphoblastoid cells and open new venues to understand
both the antineoplastic effect and the clinical side effects of the
drug.
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